Enzalutamide Soft Capsules are a medication for patients with advanced prostate cancer. It is primarily indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of metastasis, and for adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.

Data released by the International Agency for Research on Cancer (IARC) shows that in 2022, there were 1.467 million new cases of prostate cancer globally, making it the second most common cancer in men. Incidence rates often increase with age, starting to rise at age 50 and peaking in the 65-80 age group. According to an analysis by the "Medical Horizon" public account, prostate cancer (PCa) is the most common cancer among men in Europe, America, Australia, and sub-Saharan Africa. It is the cancer with the highest incidence in 114 countries and the leading cause of cancer death in 56 countries. From 2007 to 2017, the global incidence of PCa increased by 42%. In Brazil, there are 62 new cases per 100,000 men. Incidence is higher in more developed regions and among African Americans. In 2022, prostate cancer accounted for 23.2% of new cancer cases in men in 27 EU countries.

As a new generation key drug for prostate cancer treatment, enzalutamide demonstrates significant efficacy and safety. It is currently the androgen receptor (AR) inhibitor with the broadest range of prostate cancer indications, representing a huge market demand. Data from Menet.cn shows that enzalutamide's global sales exceeded $5 billion in 2023.

Qingfeng Pharmaceutical is accelerating its international development process. In the next 5 years, the company plans to pursue comprehensive registration and market promotion in the United States, Europe, and emerging markets, committed to providing global patients with better product choices and services to benefit patients worldwide.